Related Experiment Videos
Contraception with subdermal implants releasing the progestin ST-1435: a dose-finding study
M Haukkamaa1, M Laurikka-Routti, O Heikinheimo
1Department of Medical Chemistry, University of Helsinki, Finland.
Contraception
|January 1, 1992
Summary
A novel subdermal implant using ST-1435 effectively inhibits ovulation for contraception. A 4 cm implant is optimal, providing two years of protection with minimal side effects.
Area of Science:
- Reproductive Endocrinology
- Contraception Development
- Pharmacokinetics
Background:
- Subdermal implants offer long-term reversible contraception.
- Novel progestins are continuously sought for improved contraceptive efficacy and safety.
Purpose of the Study:
- To evaluate the efficacy of a new subdermal implant releasing ST-1435 for ovulation inhibition.
- To determine the optimal implant length for effective contraception.
Main Methods:
- Eleven fertile-aged women received subdermal implants of varying lengths (4, 6, 8 cm) releasing ST-1435.
- Serum hormone levels (ST-1435, estradiol, progesterone) were monitored via RIA over six months.
- Ovulation inhibition was assessed by progesterone levels.
Main Results:
- All tested doses of ST-1435 successfully inhibited ovulation, indicated by progesterone levels below 6 nmol/l.
- ST-1435 serum concentrations correlated positively with implant dose.
- Estradiol levels showed variability but did not differ significantly across doses.
Conclusions:
- A single 4 cm subdermal implant releasing ST-1435 is optimal for contraception, effectively inhibiting ovulation.
- This formulation provides a promising two-year contraceptive option with minimized hormonal side effects.
- Further research may be needed to address variable bleeding patterns.
Keywords:
BiologyContraceptionContraceptive Agents, Female--administraction and dosageContraceptive Agents, Progestin--administraction and dosageContraceptive Agents--administraction and dosageContraceptive ImplantsContraceptive MethodsContraceptive Mode Of ActionContraceptive UsageDeveloped CountriesEndocrine SystemEstradiol--analysisEstrogensEuropeEvaluationExaminations And DiagnosesFamily PlanningFinlandHematologic TestsHormonesLaboratory Examinations And DiagnosesLaboratory ProceduresMenstrual CycleMenstruationMethod AcceptabilityNorthern EuropeOvulation SuppressionPhysiologyProgestational HormonesProgesterone--analysisReproductionScandinavia